John Ervin

1.6k citations

20 papers · 677 indexed · 1 hit paper · h-index 13

Impact in

Infectious Diseases top 10%
- Viral gastroenteritis research and epidemiology
Rheumatology top 10%
- Osteoarthritis Treatment and Mechanisms

Papers in ⓘ

Epidemiology 12
- Respiratory viral infections research 10
- Influenza Virus Research Studies 4
- Pneumonia and Respiratory Infections 3
Rheumatology 5
- Osteoarthritis Treatment and Mechanisms 5

Co-authors: Alan Kivitz (2 shared papers)Haobo Ren (1 shared paper)Paul J. Tiseo (1 shared paper)Scott Mellis (1 shared paper)Randall M. Stevens (2 shared papers)P Hanson (2 shared papers)Robin Burges (2 shared papers)James N. Campbell (1 shared paper)
Journals: Open Forum Infectious Diseases (4 papers)Human Vaccines & Immunotherapeutics (2 papers)Arthritis & Rheumatology (2 papers)The Lancet Infectious Diseases (2 papers)New England Journal of Medicine (1 paper)
Partner nations: United States Belgium Netherlands

In The Last Decade

John Ervin

20 papers receiving 652 citations

Hit Papers

align trajectories log scale

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults 2023 · 90 citations

Peers

Countries citing papers authored by John Ervin

Since Specialization

Citations

This map shows the geographic impact of John Ervin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ervin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ervin more than expected).

Fields of papers citing papers by John Ervin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ervin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ervin. The network helps show where John Ervin may publish in the future.

Co-authors

The 25 scholars most cited alongside John Ervin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Ervin Line = papers co-authored together John Ervin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study The Lancet Infectious Diseases ·Marc Gurwith, Michael Lock, Eve M. Taylor, Glenn Ishioka, Jeff Alexander, Tim Mayall, John Ervin, Richard N. Greenberg, Cynthia Strout, John J. Treanor, Richard J. Webby, Peter F. Wright	2013	122
2	Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults New England Journal of Medicine ·Ann R. Falsey, Kristi L. Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Christy Comeaux, Esther Heijnen Hit paper breakdown →	2023	90
3	Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee Pain ·Paul J. Tiseo, Alan Kivitz, John Ervin, Haobo Ren, Scott Mellis	2014	88
4	Randomized, Double‐Blind, Placebo‐Controlled Trial of Intraarticular Trans ‐ Capsaicin for Pain Associated With Osteoarthritis of the Knee Arthritis & Rheumatology ·Randall M. Stevens, John Ervin, J. Nezzer, Yeni Nieves, K.J.T. Guedes, Robin Burges, P Hanson, James N. Campbell	2019	84
5	Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial The Lancet Infectious Diseases ·Robert W. Frenck, John Ervin, Laurence Chu, Darren Abbanat, Bart Spiessens, Oscar Go, Wouter Haazen, Germie van den Dobbelsteen, Jan Poolman, S Thoelen, Patricia Palacios	2019	57
6	A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee PLoS ONE ·David Bar‐Or, Kristin Salottolo, Holli Loose, Matthew J. Phillips, Brian J. McGrath, Nathan Wei, James Borders, John Ervin, Alan Kivitz, Martin Hermann, Tammi Shlotzhauer, Melvin Churchill, Donald Slappey, Vaughan Clift	2014	41
7	Civamide Cream 0.075% in Patients with Osteoarthritis of the Knee: A 12-Week Randomized Controlled Clinical Trial with a Longterm Extension The Journal of Rheumatology ·Thomas J. Schnitzer, Jean‐Pierre Pelletier, DOUG M. HASELWOOD, W. Ellison, John Ervin, Richard D. Gordon, Jeffrey Lisse, W. Tad Archambault, Allan R. Sampson, HEIDI B. FEZATTE, Scott B. Phillips, Joel E. Bernstein	2011	30
8	Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses Clinical and Vaccine Immunology ·Judith Falloon, H. Keipp Talbot, Craig Curtis, John Ervin, Diane Krieger, Filip Dubovsky, Therese Takas, Jing Yu, Yu Li, Stacie Lambert, Tonya Villafana, Mark T. Esser	2017	30
9	Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial International Journal of Infectious Diseases ·Robyn Hartvickson, Marilou Cruz, John Ervin, Donald M. Brandon, Eduardo Forleo‐Neto, Alemnew F. Dagnew, Richa Chandra, Kelly Lindert, Ahmed Abdul Mateen	2015	26
10	Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial Arthritis & Rheumatology ·Dinesh Khanna, Paul H. Caldron, Richard W. Martin, Suzanne Kafaja, Robert Spiera, Shadi Shahouri, Ankoor R. Shah, Vivien Hsu, John Ervin, Robert W. Simms, Robyn T. Domsic, Virginia Steen, Laura K. Hummers, Chris T. Derk, Maureen D. Mayes, Soumya Chatterjee, John Varga, Steven Kesten, John K. Fraser, Daniel E. Furst	2022	20
11	Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial The Journal of Infectious Diseases ·Tino F. Schwarz, Shinn-Jang Hwang, Pedro Ylisastigui, Chiu-Shong Liu, Kenji Takazawa, Makoto Yono, John Ervin, Charles P. Andrews, Charles Fogarty, Tamara Eckermann, Delphine Collete, Magali de Heusch, Nathalie De Schrevel, Bruno Salaun, Axel Lambert, Céline Maréchal, Aurélie Olivier, Phoebe Nakanwagi, Marc Lievens, Veronica Hulstrøm	2023	16
12	Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study PLoS neglected tropical diseases ·Vianney Tricou, Brandon Essink, John Ervin, M. Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, Derek Wallace	2023	16
13	Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age Vaccine ·Geoffrey J. Gorse, Ann R. Falsey, Carol M. Johnson, Dennis Morrison, David L. Fried, John Ervin, David P. Greenberg, Ayca Ozol-Godfrey, Victoria Landolfi, Peter H. Tsang	2013	16
14	Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older Human Vaccines & Immunotherapeutics ·Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea Likos Krick, Tina M. Sterling, Meihua Wang, Jason Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel, Luwy Musey, (unknown)	2021	10
15	OP0167 Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study Annals of the Rheumatic Diseases ·Randall M. Stevens, D Petersen, John Ervin, J. Nezzer, Yelene Tápanes Nieves, John Campbell, K.J.T. Guedes, Robin Burges, P Hanson	2017	10
16	LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study Open Forum Infectious Diseases ·Ann R. Falsey, Kristi L. Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, H. D. Boer, Sjoukje Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Christy Comeaux, Esther Heijnen	2021	10
17	96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination Open Forum Infectious Diseases ·Tino F. Schwarz, Shinn-Jang Hwang, Pedro P Ylisastigui, Chiu-Shong Liu, Kenji Takazawa, Makoto Yono, John Ervin, Charles P. Andrews, Charles Fogarty, Tamara Eckermann, Delphine Collete, Magali de Heusch, Nathalie De Schrevel, Bruno Salaun, Marc Lievens, Céline Maréchal, Phoebe Nakanwagi, Veronica Hulstrøm	2022	4
18	A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity Human Vaccines & Immunotherapeutics ·Ute Klinkhardt, Mirjam Schunk, John Ervin, Christoph Schindler, Danny Sugimoto, Bruce Rankin, Ralf Amann, Martina Monti, Anna Kutschenko, Carsten Schumacher, Kristina Huber, Andreas Zeder, Nelli Heikkilä, Arnaud M. Didierlaurent, S. Schwarz, Madiha Derouazi	2024	3
19	2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level Open Forum Infectious Diseases ·Christy Comeaux, Ann R. Falsey, Kristi Williams, Stephan Bart, John Ervin, Arangassery Rosemary Bastian, Joris Menten, Els De Paepe, Sjouke Vandenberghe, Eric K. H. Chan, Jerald Sadoff, Macaya Douoguih, Benoît Callendret, Esther Heijnen	2022	2
20	119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination Open Forum Infectious Diseases ·Tino F. Schwarz, Shinn-Jang Hwang, Pedro P Ylisastigui, Chiu-Shong Liu, Kenji Takazawa, Makoto Yono, John Ervin, Charles P. Andrews, Charles Fogarty, Tamara Eckermann, Miguel Hernán Vicco, Marc Lievens, Céline Maréchal, Phoebe Nakanwagi, Veronica Hulstrøm	2022	2

About John Ervin

John Ervin is a scholar working on Epidemiology, Rheumatology, Immunology, Pharmacology and Molecular Medicine, having authored 20 papers that have together received 677 indexed citations. Recurring topics across this work include Respiratory viral infections research (10 papers), Osteoarthritis Treatment and Mechanisms (5 papers), Influenza Virus Research Studies (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Inflammatory mediators and NSAID effects (4 papers), Tracheal and airway disorders (3 papers), Pneumonia and Respiratory Infections (3 papers) and Pain Mechanisms and Treatments (2 papers). The work is most often cited by research in Infectious Diseases (179 citations), Rheumatology (133 citations), Sensory Systems (41 citations), Epidemiology (270 citations) and Endocrinology (39 citations). John Ervin has collaborated with scholars based in United States, Belgium and Netherlands. Frequent co-authors include Alan Kivitz, Haobo Ren, Paul J. Tiseo, Scott Mellis, Randall M. Stevens, P Hanson, Robin Burges, James N. Campbell, Glenn Ishioka and Peter F. Wright. Their work appears in journals such as Open Forum Infectious Diseases, Human Vaccines & Immunotherapeutics, Arthritis & Rheumatology, The Lancet Infectious Diseases and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact